Abstract | BACKGROUND: METHODS: Patients diagnosed with influenza by rapid diagnostic kit underwent treatment in one of the following groups: Maoto-treated group (group 1 (M)); oseltamivir-treated group (group 2 (O)); Maoto+oseltamivir-treated group (group 3 (M+O)); zanamivir-treated group (group 4 (Z)); and Maoto+zanamivir-treated group (group 5 (M+Z)). RESULTS: In influenza A patients who completed the study (n = 150), the mean duration of fever after administration (DFA) was significantly shorter in group 3 (M+O) (31.1 h, p < 0.01) and in group 4 (Z) (35.2 h, p < 0.05), as compared to group 2 (O) (56.0 h). Among these, in patients aged ≤5 years (n = 54), DFA was significantly shorter in group 1 (M) (33.2 h, p < 0.05) and in group 3 (M+O) (34.6 h, p < 0.05), as compared to group 2 (O) (61.4 h). In influenza B patients who completed the study (n = 70), no significant differences in DFA were observed among the groups. CONCLUSION:
|
Authors | Yoshitaka Toriumi, Tsutomu Kamei, Kohji Murata, Ikuko Takahashi, Nobutaka Suzuki, Osam Mazda |
Journal | Forschende Komplementarmedizin (2006)
(Forsch Komplementmed)
Vol. 19
Issue 4
Pg. 179-86
( 2012)
ISSN: 1661-4127 [Electronic] Switzerland |
PMID | 22964983
(Publication Type: Comparative Study, Controlled Clinical Trial, Journal Article)
|
Copyright | Copyright © 2012 S. Karger AG, Basel. |
Chemical References |
- Antiviral Agents
- Drugs, Chinese Herbal
- Mao-to
- Oseltamivir
- Zanamivir
|
Topics |
- Administration, Inhalation
- Administration, Oral
- Adolescent
- Age Factors
- Antiviral Agents
(therapeutic use)
- Child
- Child, Preschool
- Drug Therapy, Combination
- Drugs, Chinese Herbal
(therapeutic use)
- Female
- Humans
- Infant
- Influenza, Human
(drug therapy)
- Influenzavirus A
(drug effects)
- Influenzavirus B
(drug effects)
- Male
- Oseltamivir
(therapeutic use)
- Seasons
- Treatment Outcome
- Zanamivir
(therapeutic use)
|